As Philadelphia continues to garner the interest of companies like WuXi AppTec and SK, a Quebec-based CRO is also looking to expand manufacturing operations in the City of Brotherly Love on behalf of a client.
Altasciences, a drug formulation and manufacturing CRO, is constructing a manufacturing facility for California-based Alladapt Immunotherapeutics in the greater Philadelphia area. Alladapt is currently developing a precision therapeutic to address IgE-mediated food allergies.
As reported last year, Altasciences has been contracted to construct the 53,000-square-foot building. The project, whose cost was not disclosed to Endpoints News, is scheduled to be completed sometime in 2023, but no exact date was confirmed.
However, Alladapt did secure a $119 million financing round in June, which will go toward a buildout of a manufacturing facility as well as the development of a lead product candidate, and trial preparation.
Altasciences will manage all aspects of the project, including warehousing, release management, manufacturing, quality assurance and finished product release. According to Altasciences, their client has developed the formulation and manufacturing processes for the facility.
“We are pleased to continue supporting Alladapt in their important goal of developing a single therapeutic to address a wide range of mono- and multi-food allergies, and we look forward to fulfilling their Phase III and commercial requirements,” said Ben Reed, the general manager of CDMO Services at Altasciences, in a statement.
According to Alladapt, their lead candidate, dubbed ADP101, is being developed for the mitigation of food allergies that can be provoked by either single or multiple proteins from a variety of different foods. The drug is based on an intellectual property estate that includes patents and accompanying clinical data licensed from Stanford University.
For its part, Altasciences has been steadily growing in the US, as the company last year acquired spaces in Los Angeles and acquired Calvert Laboratories, a preclinical CRO in Pennsylvania, building out its presence on the coasts.
The company in January acquired Sinclair Research, a preclinical CRO in Missouri, gaining 80 animal rooms, and full-service IND and NDA-enabling toxicology and safety pharmacology services.